Search
Pliant Therapeutics Inc
PLRXAdd to Watchlist
1.140USD
+0.030+2.70%
Market hours （ET）Quotes delayed by 15 min
70.58MMarket Cap
LossP/E TTM
More Details of Pliant Therapeutics Inc Company
Pliant Therapeutics, Inc. is a late-stage biotechnology company, which is focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. The Company’s lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of avb6 and avb1 integrins that is in development in the lead indication for the treatment of idiopathic pulmonary fibrosis, or idiopathic pulmonary fibrosis (IPF). The Company’s second clinical program, PLN-101095, is a small molecule, dual selective inhibitor of integrins avb8 and avb1 for the treatment of solid tumors that are resistant to immune checkpoint inhibitors. Its Phase 1-ready program PLN-101325, is in development for treatment of muscular dystrophies, including Duchenne muscular dystrophy. PLN-101325 is a monoclonal antibody designed to act as an allosteric agonist of integrin a7b1.
Pliant Therapeutics Inc Info
Ticker SymbolPLRX
Company namePliant Therapeutics Inc
IPO dateJun 03, 2020
CEOCoulie (Bernard J)
Number of employees171
Security typeOrdinary Share
Fiscal year-endJun 03
Address331 Oyster Point Boulevard
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94080
Phone16504816770
Websitehttps://pliantrx.com/
Ticker SymbolPLRX
IPO dateJun 03, 2020
CEOCoulie (Bernard J)
Company Executives of Pliant Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Bernard J. Coulie, M.D., Ph.D.
Dr. Bernard J. Coulie, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
766.87K
+19.64%
Dr. Hoyoung Huh, M.D., Ph.D.
Dr. Hoyoung Huh, M.D., Ph.D.
Non-Executive Chairman of the Board, Lead Independent Director
Non-Executive Chairman of the Board, Lead Independent Director
99.76K
--
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Independent Director
Independent Director
35.08K
--
Dr. John T. Curnutte, M.D., Ph.D.
Dr. John T. Curnutte, M.D., Ph.D.
Independent Director
Independent Director
29.28K
--
Ms. Lily Cheung
Ms. Lily Cheung
Chief Human Resources Officer
Chief Human Resources Officer
18.93K
+61.88%
Dr. Eric Lefebvre, M.D.
Dr. Eric Lefebvre, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Keith Cummings, M.D.
Dr. Keith Cummings, M.D.
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Gayle Crowell
Ms. Gayle Crowell
Independent Director
Independent Director
--
--
Mr. Christopher Keenan
Mr. Christopher Keenan
Vice President - Investor Relations and Corporate Communications
Vice President - Investor Relations and Corporate Communications
--
--
Mr. David E. I. Pyott, CBE
Mr. David E. I. Pyott, CBE
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Bernard J. Coulie, M.D., Ph.D.
Dr. Bernard J. Coulie, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
766.87K
+19.64%
Dr. Hoyoung Huh, M.D., Ph.D.
Dr. Hoyoung Huh, M.D., Ph.D.
Non-Executive Chairman of the Board, Lead Independent Director
Non-Executive Chairman of the Board, Lead Independent Director
99.76K
--
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Independent Director
Independent Director
35.08K
--
Dr. John T. Curnutte, M.D., Ph.D.
Dr. John T. Curnutte, M.D., Ph.D.
Independent Director
Independent Director
29.28K
--
Ms. Lily Cheung
Ms. Lily Cheung
Chief Human Resources Officer
Chief Human Resources Officer
18.93K
+61.88%
Dr. Eric Lefebvre, M.D.
Dr. Eric Lefebvre, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
FAQs
Who are the top five shareholders of Pliant Therapeutics Inc?
The top five shareholders of Pliant Therapeutics Inc are: Dr. Bernard J. Coulie, M.D., Ph.D.
How many institutions hold shares of Pliant Therapeutics Inc (PLRX)?
As of 2026Q1, 360 institutions hold shares of Pliant Therapeutics Inc, with a combined market value of approximately 50.65M, accounting for 81.81% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -48746249.00.